文献速递白血病造血干细胞移植与细胞治疗

靶向CD300f增强急性髓系白血病造血干细胞移植

Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该研究开发了一种抗CD300f抗体偶联药物(ADC),其表达量与CD33相当,可高效内化并选择性清除AML细胞及集落形成单位,与氟达拉滨协同。在小鼠模型中单次注射可延长生存、清除原代人AML并耗竭CD34+造血干祖细胞,有望降低移植前预处理毒性和移植后复发。

要点

  • 抗CD300f ADC在体外选择性清除AML细胞系和集落形成单位。
  • ADC与氟达拉滨协同,可作为低毒性预处理方案的组合。
  • 人源化小鼠单次注射ADC可耗竭CD34+ HSPC及造血干细胞。

核心结论

  • 抗CD300f ADC是一种有吸引力的潜在治疗手段,若在更大规模原代AML样本的移植模型中验证,可降低接受allo-HSCT的AML患者的复发率和毒性。

研究设计与样本

  • 临床前研究:开发抗CD300f抗体及以吡咯并苯二氮卓为弹头的ADC,在体外细胞系、原代细胞及人源化小鼠模型中评估。

主要发现

  • CD300f在HSPC各亚型中均匀表达,在AML上的转录和蛋白表达水平与CD33相当。
  • 抗CD300f ADC在体外选择性清除AML细胞系和集落形成单位,并与氟达拉滨协同。
  • ADC延长了植入人细胞系小鼠的生存,单次注射可清除植入的原代人AML。
  • 在人源化小鼠模型中,单次注射ADC可耗竭CD34+ HSPC和CD34+CD38-CD90+造血干细胞。

临床怎么用

  • 若临床验证成功,抗CD300f ADC可作为低毒性预处理方案的一部分,用于接受allo-HSCT的AML患者。

局限性

  • 结果需在更大规模原代AML样本的移植模型中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) significantly reduces the rate of relapse in acute myeloid leukemia (AML) but comes at the cost of significant treatment-related mortality. Despite the reduction in relapse overall, it remains common, especially in high-risk groups. The outcomes for patients who relapse after transplant remains very poor. A large proportion of the morbidity that prevents most patients from accessing allo-HSCT is due to toxic nonspecific conditioning agents that are required to remove recipient hematopoietic stem and progenitor cells (HSPCs), allowing for successful donor engraftment. CD300f is expressed evenly across HSPC subtypes. CD300f has transcription and protein expression equivalent to CD33 on AML. We have developed an anti-CD300f antibody that efficiently internalizes into target cells. We have generated a highly potent anti-CD300f antibody-drug conjugate (ADC) with a pyrrolobenzodiazepine warhead that selectively depletes AML cell lines and colony forming units in vitro. The ADC synergizes with fludarabine, making it a natural combination to use in a minimal toxicity conditioning regimen. Our ADC prolongs the survival of mice engrafted with human cell lines and depletes primary human AML engrafted with a single injection. In a humanized mouse model, a single injection of the ADC depletes CD34+ HSPCs and CD34+CD38-CD90+ hematopoietic stem cells. This work establishes an anti-CD300f ADC as an attractive potential therapeutic that, if validated in transplant models using a larger cohort of primary AML samples, will reduce relapse rate and toxicity for patients with AML undergoing allo-HSCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Abadir E, Silveira PA, Gasiorowski RE, et al. Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia. Blood Adv. 2020. PMID: 32215656. doi:10.1182/bloodadvances.2019001289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。